UBS Group’s TuHURA Biosciences HURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $111K | Buy |
62,066
+33,935
| +121% | +$41.6K | ﹤0.01% | 6957 |
|
|
2025
Q4 | $21.3K | Sell |
28,131
-113,344
| -80% | -$217K | ﹤0.01% | 7740 |
|
|
2025
Q3 | $351K | Sell |
141,475
-114,529
| -45% | -$301K | ﹤0.01% | 6336 |
|
|
2025
Q2 | $571K | Buy |
256,004
+143,869
| +128% | +$486K | ﹤0.01% | 5894 |
|
|
2025
Q1 | $362K | Buy |
112,135
+18,802
| +20% | +$69.4K | ﹤0.01% | 6102 |
|
|
2024
Q4 | $382K | Buy |
93,333
+90,368
| +3,048% | +$480K | ﹤0.01% | 6032 |
|
|
2024
Q3 | $20.2K | Buy |
2,965
+799
| +37% | +$5.94K | ﹤0.01% | 7369 |
|
|
2024
Q2 | $20.5K | Sell |
2,166
-1,795
| -45% | -$11.2K | ﹤0.01% | 7290 |
|
|
2024
Q1 | $14.4K | Buy |
+3,961
| New | +$15.9K | ﹤0.01% | 7070 |
|
|
2023
Q3 | – | Sell |
-2
| Closed | -$262 | – | 10067 |
|
|
2023
Q2 | $262 | Sell |
2
-59
| -97% | -$6.71K | ﹤0.01% | 8344 |
|
|
2023
Q1 | $7.55K | Buy |
61
+21
| +53% | +$4.05K | ﹤0.01% | 7798 |
|
|
2022
Q4 | $9.67K | Buy |
40
+12
| +43% | +$2.67K | ﹤0.01% | 8622 |
|
|
2022
Q3 | $5K | Buy |
28
+26
| +1,300% | +$8.31K | ﹤0.01% | 9246 |
|
|
2022
Q2 | $1K | Hold |
2
| – | – | ﹤0.01% | 9998 |
|
|
2022
Q1 | $2K | Hold |
2
| – | – | ﹤0.01% | 9687 |
|
|
2021
Q4 | $2K | Hold |
2
| – | – | ﹤0.01% | 9845 |
|
|
2021
Q3 | $3K | Sell |
2
-1
| -33% | -$2.63K | ﹤0.01% | 8852 |
|
|
2021
Q2 | $13K | Hold |
3
| – | – | ﹤0.01% | 7813 |
|
|
2021
Q1 | $8K | Buy |
+3
| New | +$10.2K | ﹤0.01% | 8102 |
|
|
2020
Q4 | – | Sell |
-3
| Closed | -$7.52K | – | 8265 |
|
|
2020
Q3 | $7K | Sell |
3
-2
| -40% | -$4.03K | ﹤0.01% | 7149 |
|
|
2020
Q2 | $6K | Buy |
+5
| New | +$6.4K | ﹤0.01% | 7321 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | -$6K | – | 8218 |
|
|
2019
Q1 | $6K | Sell |
1
-1
| -50% | -$6.79K | ﹤0.01% | 7105 |
|
|
2018
Q4 | $11K | Buy |
+2
| New | +$19.4K | ﹤0.01% | 7197 |
|
|
2018
Q3 | – | Sell |
-1
| Closed | -$7K | – | 8326 |
|
|
2018
Q2 | $7K | Hold |
1
| – | – | ﹤0.01% | 7355 |
|
|
2018
Q1 | $16K | Hold |
1
| – | – | ﹤0.01% | 6578 |
|
|
2017
Q4 | $13K | Buy |
+1
| New | +$15.5K | ﹤0.01% | 6877 |
|
|
2017
Q3 | – | Hold |
0
| – | -$7K | – | 8050 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6993 |
|
|
2017
Q1 | – | Hold |
0
| – | -$1K | – | 8045 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7653 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6927 |
|
Other funds holding HURA
VCM
VFT
VPM
AWM
UBS Group's HURA Position: Q1 2026 in Review
UBS Group increased its TuHURA Biosciences (HURA) stake by 121% in Q1 2026, buying an estimated $41.6K and bringing the position to 62,066 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #6957.
UBS Group first reported a position in HURA in Q4 2017 and has held it in 26 quarters since. The position peaked at $571K in Q2 2025. 89 funds tracked by Wall St. Rank hold HURA as of Q1 2026.
- UBS Group held 62,066 shares of TuHURA Biosciences worth $111K as of Q1 2026.
- UBS Group bought 33,935 TuHURA Biosciences shares in Q1 2026, an estimated $41.6K.
- TuHURA Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6957 holding.
- UBS Group first reported a position in TuHURA Biosciences in Q4 2017 and has held it in 26 quarters since.
- UBS Group's TuHURA Biosciences position peaked at $571K in Q2 2025.
- 89 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.